Sep. 2 at 5:44 PM
$CUE — SELL 🔴
Cash is only
$27.1M against an accumulated deficit of
$368.5M, while operating cash flow is -
$50.05M and levered free cash flow is -
$33.43M.
Q1 2026 revenue was
$5.69M versus
$0.421M in Q1 2025, but the business still posted EBITDA of $-4.25M and net income of $-5.18M.
Valuation is still rich for a pre-profit biotech at 5.2x Price/Sales and 5.1x EV/Revenue, with forward EPS at -
$0.5 and forward P/E at -56.3x.
The patent estate is real, with 161 issued patents and 308 pending patent applications, but 2 analysts and a current ratio of 1.255x do not offset the burn and dilution risk.
Full research: https://lf0.com/research/cue-biopharma-stock-analysis-cue/?utm_source=stocktwits&utm_medium=social&utm_campaign=research_distribution
